Fintel reports that on January 14, 2025, Craig-Hallum initiated coverage of LifeVantage (NasdaqCM:LFVN) with a Buy ...

LifeVantage (LFVN) announced the results of a third-party cell study on the synergistic impact of Protandim Nrf2 Synergizer ...

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

Craig-Hallum analyst Alex Fuhrman initiated coverage of LifeVantage (LFVN) with a Buy rating and $35 price target Discover ...

LifeVantage Corporation (Nasdaq: LFVN), a leader in cellular activation of optimal health processes, today announced the results of a groundbreaking third-party cell study on the synergistic impact of ...

As previously reported, Craig-Hallum initiated coverage of LifeVantage (LFVN) with a Buy rating and $35 price target Interest in weight loss ...

As the U.S. stock market navigates a mixed landscape with the S&P 500 inching higher and tech stocks experiencing volatility, investors are keenly observing growth companies with substantial insider ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

LifeVantage (NASDAQ:LFVN) soared in Wednesday trading after the company updated guidance earlier in the day. For FQ2, LifeVantage (NASDAQ:LFVN) sees revenue of $67.5 million vs. $51.5 million ...

LifeVantage shares soared Wednesday after the company said its financial outlook for 2025 is brighter than previously expected. The health and nutrition company's stock rose 30% to $21.40 in morning ...

(RTTNews) - LifeVantage Corp. (LFVN), a health and wellness company, on Wednesday reported a rise in preliminary revenue for the second quarter, helped by strong sales and business momentum.

LifeVantage Corp. engages in the identification, research, development, formulation, and sale of nutraceutical dietary supplements and personal care products. Its products include Protandim ...